Unknown

Dataset Information

0

MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.


ABSTRACT:

Purpose

More accurate prediction of patient outcome based on molecular subtype is required to identify patients who will benefit from specific treatments.

Methods

We selected novel 16 candidate prognostic genes, including 10 proliferation-related genes (p-genes) and 6 immune response-related genes (i-genes), from the gene list identified in our previous study. We then analyzed the association between their expression, measured by quantitative real-time reverse transcription-PCR in formalin-fixed, paraffin-embedded tissues, and clinical outcome in 819 breast cancer patients according to molecular subtype.

Results

The prognostic significance of clinical and gene variables varied according to the molecular subtype. Univariate analysis showed that positive lymph node status was significantly correlated with the increased risk of distant metastasis in all subtypes except the hormone receptor-negative, HER2-positive (HR-/HER2+) subtype. Most p-genes were significantly associated with poor prognosis in patients with the HR+/HER2- subtype, whereas i-genes correlated with a favorable outcome in patients with HR-/HER2+ breast cancer. In HR-/HER2+ breast cancer, four genes (three i-genes BTN3A2, CD2, and TRBC1 and the p-gene MMP11) were significantly associated with distant metastasis-free survival (DMFS). A new prognostic model for HR-/HER2+ breast cancer based on the expression of MMP11 and CD2 was developed and the DMFS for patients in the high-risk group according to our model was significantly lower than that for those in the low-risk group. Multivariate analyses revealed that our risk score is an independent prognostic factor for DMFS. Moreover, C-index showed that our risk score has a superior prognostic performance to traditional clinicopathological factors.

Conclusions

Our new prognostic model for HR-/HER2+ breast cancer provides more accurate information on the risk of distant metastasis than traditional clinical prognostic factors and may be used to identify patients with a good prognosis in this aggressive subtype of breast cancer.

SUBMITTER: Han J 

PROVIDER: S-EPMC5487710 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.

Han Jinil J   Choi Yoon-La YL   Kim Haein H   Choi Jun Young JY   Lee Se Kyung SK   Lee Jeong Eon JE   Choi Joon-Seok JS   Park Sarah S   Choi Jong-Sun JS   Kim Young Deug YD   Nam Seok Jin SJ   Nam Byung-Ho BH   Kwon Mi Jeong MJ   Shin Young Kee YK  

Breast cancer research and treatment 20170413 1


<h4>Purpose</h4>More accurate prediction of patient outcome based on molecular subtype is required to identify patients who will benefit from specific treatments.<h4>Methods</h4>We selected novel 16 candidate prognostic genes, including 10 proliferation-related genes (p-genes) and 6 immune response-related genes (i-genes), from the gene list identified in our previous study. We then analyzed the association between their expression, measured by quantitative real-time reverse transcription-PCR in  ...[more]

Similar Datasets

| S-EPMC8384149 | biostudies-literature
| S-EPMC5049991 | biostudies-literature
| S-EPMC10797795 | biostudies-literature
| S-EPMC7275019 | biostudies-literature
| S-EPMC6001771 | biostudies-literature
| S-EPMC4651130 | biostudies-other
| S-EPMC7283275 | biostudies-literature
| S-EPMC6299331 | biostudies-literature
| S-EPMC7881184 | biostudies-literature
| S-EPMC8414540 | biostudies-literature